Skip to content

Spyre Therapeutics

US · SYRE #1646 by market cap Listed 1970
80.85 +0.74 +0.92%
Live - 5344 symbols - heartbeat 12s ago · 2026-10-08 07:00
Pre-market 80.50 -0.43%
After-hours 81.22 +0.46%
Overnight 79.62 -1.52%
Market cap
7.13B
P/B
7.47
EPS
-1.98
Reader sentiment Are you bullish or bearish on SYRE?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $116 to $130
    Market Newswire · 2026/8/27
  • Rating change
    JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $140
    Market Newswire · 2026/8/13
  • Rating change
    Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123
    Market Newswire · 2026/8/14
  • Form 144 | Spyre Therapeutics(SYRE.US) Director Proposes to Sell 4.01 Million in Common Stocks
    Market Newswire · 2026/10/2
  • Rating change
    LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $129
    Market Newswire · 2026/8/15
  • Rating change
    BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $132
    Market Newswire · 2026/8/11
  • Rating change
    Jefferies Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $126
    Market Newswire · 2026/9/9
  • JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $130
    Market Newswire · 2026/10/1
  • Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $115
    Market Newswire · 2026/10/4
  • Rating change
    LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128
    Market Newswire · 2026/8/8
  • Rating change
    A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $115 to $127
    Market Newswire · 2026/8/26
  • JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $121
    Market Newswire · 2026/9/28
  • Rating change
    LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $129
    Market Newswire · 2026/8/11
  • Rating change
    Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $130
    Market Newswire · 2026/8/6
  • Rating change
    Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $130
    Market Newswire · 2026/8/11
  • Rating change
    Leerink Partners Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128
    Market Newswire · 2026/9/9
  • J.P. Morgan Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $110
    Market Newswire · 2026/10/1
  • Rating change
    LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $116
    Market Newswire · 2026/9/9
  • Rating change
    Guggenheim Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $130
    Market Newswire · 2026/8/27
  • Rating change
    Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123
    Market Newswire · 2026/9/9

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:00:13 · For reference only, not investment advice and not tailored to your situation.